Clonal heterogeneity and tumor evolution inform treatment resistance in a patient with HER2+breast cancer

被引：0
|
作者：
Buendia-Buendia, Jorge E. [1 ]
Pernas, Sonia [2 ]
Cohen, Ofir [1 ]
Mao, Ping Ping [2 ]
Kowalski, Kailey [2 ]
Lin, Nancy [2 ]
Winer, Eric [2 ]
Wagle, Nikhil [2 ]
机构：
[1] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P3-01-09
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3-01-09
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Trastuzumab-Induced Tumor Microenvironment Changes in Early HER2+Breast Cancer
    Kennedy, Laura C.
    Alvarez, Rebeca
    Dintzis, Suzanne
    Gadi, Vijayakrishna K.
    CANCER RESEARCH, 2023, 83 (05)
  • [32] MUC4 enables immune tumor evasion in HER2+breast cancer
    Bruni, Sofia
    Mauro, Florencia L.
    Mercogliano, Maria F.
    Proietti, Cecilia J.
    Adami, Carla
    Dupont, Agustina
    Inurrigarro, Gloria
    Russo, Rosalia Cordo
    Elizalde, Patricia V.
    Schillaci, Roxana
    CANCER RESEARCH, 2022, 82 (12)
  • [33] TESTING AND TREATMENT PATTERNS IN HER2+BREAST CANCER PATIENTS IN THE ADJUVANT SETTING
    Lalla, D.
    Stepanski, E.
    Benn, L.
    Brammer, M.
    Walker, M. S.
    Schwartzberg, L.
    ANNALS OF ONCOLOGY, 2010, 21 : 343 - 343
  • [34] STAT6 expression and trastuzumab resistance in HER2+breast cancer.
    Cobleigh, Melody A.
    DiScala, Molly
    Najor, Matthew S.
    Yung, Timothy
    Abukhdeir, Abde M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer
    Janiszewska, Michalina
    Stein, Shayna
    Filho, Otto Metzger
    Eng, Jennifer
    Kingston, Natalie L.
    Harper, Nicholas W.
    Rye, Inga H.
    Aleckovic, Masa
    Trinh, Anne
    Murphy, Katherine C.
    Marangoni, Elisabetta
    Cristea, Simona
    Oakes, Benjamin
    Winer, Eric P.
    Krop, Ian
    Russnes, Hege G.
    Spellman, Paul T.
    Bucher, Elmar
    Hu, Zhi
    Chin, Koei
    Gray, Joe W.
    Michor, Franziska
    Polyak, Kornelia
    JCI INSIGHT, 2021, 6 (11)
  • [36] Soluble TNFa induced mucin 4 is a mediator of trastuzumab resistance and of an immunosuppressive tumor microenvironment in HER2+breast cancer
    Bruni, Sofia
    De Martino, Mara
    Mauro, Florencia
    Maria de la Parra, Lucia Santa
    Elizalde, Patricia
    Schillaci, Roxana
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [37] Vascular and lymphatic phenotype of HER2+breast cancer
    Tannenbaum, S.
    Rampurwala, M.
    Hegde, P.
    Jabbour, N.
    Phoenix, N.
    Claffey, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [38] Modeling the transcriptome landscape of HER2+breast cancer
    Kalari, Krishna R.
    Chai, High-Seng
    Asmann, Yan W.
    Tang, Xiaojia
    Rossell, David
    Baheti, Saurabh
    Nair, Asha
    Baker, Tiffany R.
    Necela, Brian M.
    Carr, Jennifer M.
    Hart, Steve N.
    Sun, Zhifu
    Kachergus, Jennifer M.
    Younkin, Curtis S.
    Kocher, Jean-Pierre A.
    Thompson, Aubrey E.
    Perez, Edith A.
    CANCER RESEARCH, 2012, 72
  • [39] Characterization of the immune infiltrate in HER2+breast cancer
    Ganesan, Shridar
    Alexe, Gabriela
    Hirshfield, Kim M.
    Yao, Ming
    Bhanot, Gyan
    Deborah, Toppmeyer
    CANCER RESEARCH, 2015, 75
  • [40] Effect of FAK Activation HER2+Breast Cancer
    Quintana, Victoria Gabriela
    Byrd, Sherell
    FASEB JOURNAL, 2019, 33
12345